Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective vigilantly but unsuccessfully to develop a single therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be being used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV happen to be closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the last several shares of mine. The first CytoDyn post of mine, “CytoDyn: What to be able to Do When It’s Too Good to be able to Be True?”, set out the following prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan presented such a highly marketing image in the Uptick Newswire interview that I came away with a poor impression of the company.

Irony of irony, my poor opinion of the business has grown steadily, though the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger at the moment still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV infected subjects. Today’s payment of $3.5 million transfers ownership of the know-how and associated intellectual property coming from Progenics to CytoDyn, and also approximately twenty five million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 huge number of) along with the very first brand new drug program approval ($five million), as well as royalty payments of five percent of net sales upon commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many indications and many therapies, it has this individual remedy and a “broad pipeline of indications” as it places it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy of dozens of indications.

Its opening banner on its website (below) shows an active organization with diverse interests albeit centered on leronlimab, multiple illness types, multiple delivering presentations in addition to multiple publications.

Could all of it be smoke and mirrors? That’s a question I have been asking myself from the very start of the interest of mine in this particular company. Judging with the multiples of a huge number of diverse remarks on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this question.

CytoDyn is a classic battleground, or perhaps some might say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *